We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Blow to Pipelines: Interchangeability Likely to Require Clinical Data
Blow to Pipelines: Interchangeability Likely to Require Clinical Data
September 25, 2012
The FDA appears poised to require clinical trial data from drugmakers seeking interchangeability designations for biosimilars, a move that could shrink the number of products aiming to achieve the standard, drugmakers and legal experts say.